Ret Proto-Oncogene Antikörper (C-Term, Leu1027)
Kurzübersicht für Ret Proto-Oncogene Antikörper (C-Term, Leu1027) (ABIN2350377)
Target
Alle Ret Proto-Oncogene (RET) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 1012-1042, C-Term, Leu1027
-
Kreuzreaktivität
- Human
-
Kreuzreaktivität (Details)
- Calculated cross reactivity: Hu
-
Produktmerkmale
- RET, CT (L1027) (RET, CDHF12, CDHR16, PTC, RET51, Proto-oncogene tyrosine-protein kinase receptor Ret, Cadherin family member 12, Proto-oncogene c-Ret, Soluble RET kinase fragment, Extracellular cell-membrane anchored RET cadherin 120kD fragment)
-
Aufreinigung
- Purified by Ammonium Sulfate Precipitation.
-
Immunogen
- KLH-conjugated synthetic peptide mapping to a fragment of residues within amino acids 1012-1042 in the C-terminal region of Human RET UniProt Accession #P07949.
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working conditions should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C
-
-
- Ret Proto-Oncogene (RET)
-
Andere Bezeichnung
- RET
-
UniProt
- P07949
-
Pathways
- RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Target
-